Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1998-12-15
2001-01-16
Elliott, George C. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S069100, C435S455000, C536S023100, C536S023500
Reexamination Certificate
active
06174872
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to a method for treating both the early and late phases of allergic lung disease. In particular, the invention relates to a method for immunizing a host against allergic asthma through use of asthma-initiating antigen-encoding polynucleotide compositions.
2. History of the Prior Art
Asthma is one of the common chronic lung diseases of industrialized countries. The airway narrowing which characterizes the disease is associated with antigen stimulated immune system activation, including elevation of antigen-specific IgE levels in the early phase of the disease and eosinophil infiltration of lung tissue in the late phase of the disease.
Specifically, during the early phase of the disease, activation of Th2 lymphocytes stimulates the production of IgE antibody, which in turn triggers the release of histamine and other immune mediators from mast cells. During the late phase of the disease, IL-4 and IL-5 cytokine production by CD4+ helper T lymphocyte type 2 (Th2) cells is elevated. These cytokines are believed to play a significant role in recruiting eosinophils into lung tissue, where tissue damage and dysfunction result.
Persons suffering from allergic asthma are conventionally treated by immunization against the asthma-initiating antigen with an antigen-based composition. Antigen immunization limits the antigen-stimulated events of the early phase of allergic asthma, albeit at the risk of inducing IgE mediated anaphylaxis. However, such classical immunization schemes do not target the cytokine-mediated events of the late phase immune response in allergic asthma.
SUMMARY OF THE INVENTION
The invention consists of a method for treating allergic asthma in a host which reduces the allergic immune responses that are characteristic of both the early and late phases of the disease. This is accomplished according to the invention by administering an asthma-initiating antigen-encoding polynucleotide to the host in a manner which induces intracellular expression of the antigen in antigen presenting cells. The expressed antigen is presented to host CD4
+
T lymphocytes in a manner which activates class 1 helper T (Th
1
) lymphocytes in preference to Th2 lymphocytes.
Thus, the polynucleotide immunization scheme of the invention allows the clinician to induce tolerance to an asthma-initiating antigen in a host with little risk of stimulating the Th2 lymphocyte mediated IgE antibody production and mast cell activation events which characterize the early phase of allergic asthma. In addition, the immunization scheme of the invention also reduces Th2 cell release of IL-4 and IL-5, thus substantially limiting the eosinophil accumulation in lung tissue which characterizes the late phase of allergic asthma. In this manner, the invention provides a more efficacious, less risk-intensive means of treating allergic asthma than is presently available in the art.
In practice, a suitable candidate for treatment according to the method of the invention is a host in whom allergic asthma has been diagnosed and for whom at least one asthma-initiating antigen (i.e., a proteinaceous antigen which triggers an allergic response in the host that results in asthmatic symptoms being experienced by the host) has been identified.
According to the method of the invention, the host is immunized with a pharmaceutical composition comprised of a recombinant expression vector (preferably a plasmid or cosmid, hereafter “polynucleotide composition”). The recombinant expression vector incorporates a polynucleotide which encodes the asthma-initiating antigen. To enhance Th1 lymphocyte activation to a therapeutically sufficient level, the polynucleotide composition is administered to a tissue of the host which contains a relatively high concentration of antigen presenting cells (e.g., skin or mucosa, such as the mucosa of the respiratory tract) as compared to other host tissues. Advantageously, targeting the dense population of antigen presenting cells present in the skin and mucosa for expression of antigen permits relatively minute doses of polynucleotide composition to be applied toward a therapeutic effect in the lost.
Where desired, the recombinant expression vector of the polynucleotide composition may also code for other therapeutically significant, biologically active peptides, such as immunostimulatory cytokines (e.g., TGF-&bgr;). Alternatively, such peptides or other therapeutically significant compounds may be administered in conjunction with the polynucleotide compositions of the invention.
REFERENCES:
patent: 4228795 (1980-10-01), Babington
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 5780448 (1998-07-01), Davis
patent: 6008200 (1999-12-01), Krieg et al.
patent: 0 468 520 A2 (1992-01-01), None
patent: 0 620 277 (1994-10-01), None
patent: WO 90/11092 (1990-10-01), None
patent: WO 95/05853 (1995-03-01), None
patent: WO 96/03510 (1996-02-01), None
patent: WO 96/02555 A1 (1996-02-01), None
patent: WO 96/13277 (1996-05-01), None
Cohen, “Naked DNA Points Way to Vaccines”, Science, vol. 259, Mar., 1993, pp. 1691-1692.
Ulmer, et al., “Heterologous Protection Against Influenza By Injection of DNA Encoding a Viral Protein”, Science, vol. 259, Mar., 1993, pp. 1745-1749.
Tang, et al., “Genetic Immunization is a Simple Method for Eliciting an Immune Response”, Nature, vol. 356, Mar. 12, 1992, pp. 152-154.
Stribling, et al., “Aerosol Gene Deliver in vivo”, Proc. Natl. Acad. Sci. USA, vol. 89, pp. 11277-11281, Dec. 1992, Medical Sciences.
Ballas et al. (1996), “Induction of NK Activity in Murine and Human Cells by CpG Motifs in Oligodeoxynucleotides and Bacterial DNA,”Journal of Immunology,vol. 157:1840-1845.
Branda et al. (1996), “Amplification of Antibody Production by Phosphorothiate Oligodeoxynucleotides,”J. Lab. Clin. Med.,vol. 128:329-338.
Branda et al. (1993), “Immune Stimulation by an Antisense Oligomer Complementary to the rev Gene of HIV-1,”Biochemical Pharmacology,vol. 45(10):2037-2043.
Cowdery et al. (1996), “Bacterial DNA Induces NK Cells to Produce IFN-&ggr; In Vivo and Increases the Toxicity of Lipopolysaccharides,”Journal of Immunology,vol. 156:4570-4575.
Hsu et al. (May 1996), “Immunoprophylaxis of Allergen-Induced Immunoglobulin E Synthesis and Airway Hyperresponsiveness in vivo by Genetic Immunization,”Nature Medicine,vol. 2(5):540-544.
Kataoka et al. (Mar. 1992), “Antitumor Activity of Synthetic Oligonucleotides with Sequences from cDNA Encoding Proteins ofMycobacterium bovisBCG,”Jpn. J. Can. Res.,vol. 83:244-247.
Kimura et al. (1994), “Bonding of Oligoguanylate to Scavenger Receptors is Required for Oligonucleotides to Augment NK Cell Activity and Induce IFN,”J. Biochem.,vol. 116:991-994.
Klinman et al. (Apr. 1996), “CpG Motifs Present in Bacterial DNA Rapidly Induce Lymphocytes to Secrete Interleukin 6, Interleukin 12, and Interleukin &ggr;,”Proc. Natl. Acad. Sci. USA,vol. 93:2879-2883.
Krieg et al. (1996), “Oligodeoxynucleotide Modifications Determine the Magnitude of B Cell Stimulation by CpG Motifs,”Antisense and Nucleic Acid Drug Development,vol. 6:133-139.
Krieg, A. (Feb. 1996), “Lymphocyte Activation by CpG Dinucleotide Motifs in Prokaryotic DNA,”Trends in Microbiology,vol. 4(2):73-77.
Krieg et al. (Apr. 1995), “CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation,”Nature,vol. 374.
Krieg et al. (1989), “A Role for Endogenous Retroviral Sequences in the Regulation of Lymphocyte Activation,”J. Immunol.,vol. 476(8):2448-2451.
Kuramoto et al. (Nov. 1992), “Oligonucleotide Sequences Required for Natural Killer Cell Activation,”Jpn. J. Cancer Res.,vol. 83:1128-1131.
Mojcik et al. (May 1993), “Administration of a Phosphorothioate Oligonucleotide Antisense to Murine Endogenous Retroviral MCF env Causes Immune Effects in Vivo in a Sequence-Specific Manner,”Clinical Immunology and Immunopathology,vol. 67(2):130-136.
Pisetsky, D. (Oct. 1996), “Immune Activation by Bacterial DNA: A new genetic Code,”Immunity,vol. 5:303-
Carson Dennis A.
Raz Eval
Borden Paula A.
Bozicevic Field & Francis LLP
Elliott George C.
The Regents of the University of California
Zara Jane
LandOfFree
Method for treating allergic lung disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating allergic lung disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating allergic lung disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2517771